A new study published in the journal of Respiratory Medicine showed a strong correlation between a higher risk of chronic ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with COPD.

Bronchitis is a condition in which the airways in your lungs, called the Trachea and the Bronchi, get inflamed and fill with ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Cantor Fitzgerald initiated coverage of Verona Pharma (VRNA) with an Overweight rating and $80 price target The firm considers Verona one of ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

AbsoluteCare®, a value-based health care company, and CareSource Ohio are expanding their partnership to bring whole-person care to dual-eligible MyCare members who qualify for both Medicare and ...

Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com under "Investor Relations." About AdaptHealth Corp. AdaptHealth is a national leader in ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...